<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755234</url>
  </required_header>
  <id_info>
    <org_study_id>STU00070833</org_study_id>
    <nct_id>NCT01755234</nct_id>
  </id_info>
  <brief_title>Propofol Versus Sevoflurane Recovery After Gynecological Surgery</brief_title>
  <official_title>The Effects of Propofol vs. Sevoflurane Administered During Anesthesia Maintenance on Early and Late Recovery After Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      80% of 25 million American who undergo surgery describe moderate to severe pain. The use of
      multimodal analgesic techniques can attenuate patient's postoperative pain and several
      different medication have been found to be effective. Pain can significantly affect patient's
      quality of recovery after surgery. Volatile anesthetics can increase sensitivity to pain at
      the low concentrations present on emergence from anesthesia. Propofol may have analgesic
      effect at sedative doses. The effects of propofol,when used for anesthesia maintenance, on
      postoperative pain have demonstrated controversial results with some investigators showing a
      potential benefit whereas others have not shown any benefit. Propofol for maintenance of
      anesthesia has been advocated as an strategy for high risk patients even though it has shown
      controversial results on reduction of Post operative nausea and vomiting. A comparison of
      propofol vs.volatile anesthetic in regards to the time required by patients to meet discharge
      criteria has also shown conflicting results.The QOR 40 is a validated instrument that has
      been specifically developed to evaluate patients recovery after anesthesia and surgery.

      The purpose of this study is to compare the effects of maintenance of anesthesia with two
      agents (Propofol and Sevoflurane) on quality of recovery after ambulatory surgery

      Significance: the results of this study can lead to the discovery of an anesthesia technique
      that is associated with a better recovery for patients after ambulatory surgery.

      Research question is: do patients anesthetized with propofol have a better quality of
      recovery after ambulatory anesthesia than patients anesthetized with Sevoflurane? The
      hypothesis: patients anesthetized with propofol will have better quality of recovery than
      patients anesthetized with Sevoflurane after ambulatory surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be recruited up to the day of surgery. 90 subjects will be randomly allocated
      into 2 groups, using a computer generated table of random numbers: anesthetic maintenance
      with Sevoflurane or anesthetic maintenance with Propofol . Subjects will be premedicated with
      intravenous (IV) midazolam 0.04 mg/kg. Routine ASA monitors will be applied. Anesthesia will
      be induced with remifentanil infusion started at 0.1 mcg/kg/minute titrated to keep blood
      pressure within 20% of the baseline and propofol 1.0 -2.0 mg/kg or sevoflurane induction.
      Tracheal intubation will be facilitated with rocuronium (0.6 mg/kg) or succinylcholine (1-2mg
      /kg). Anesthesia will be maintained with Sevoflurane or a Propofol infusion titrated to keep
      a bispectral index between 40-60, remifentanil infusion started at 0.1mcg/kg/min titrated to
      keep blood pressure within 20 % of baseline values, and rocuronium that will be administered
      at the discretion of the anesthesiologist. Upon termination of the surgery, neuromuscular
      blockade will be antagonized with a combination of neostigmine 0.05mg/kg and glycopyrrolate
      0.01 mg/kg. Subjects will also receive Ketorolac 30 mg IV after discontinuation of
      remifentanil for postoperative pain control. Ondansetron 4 mg IV will be administered to
      decrease postoperative nausea and vomiting. Subjects will receive IV hydromorphone 0.4 mg q 5
      minutes as needed to achieve a verbal rating score for pain &lt;4 out of 10.They will also
      receive reglan 10 mg IV as a rescue antiemetic, if not effective, a second dose of Zofran 4
      mg IV will be given in PACU. 24 hours after surgery a QOR 40 will be administered to the
      patient by one of the investigators. The primary and secondary outcomes will be assessed by
      an independent observer who will be blinded to group allocation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery Score 24 Hours Post Operative</measure>
    <time_frame>24 hours after the surgical procedure</time_frame>
    <description>Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mg of Morphine Equivalents (IV)</measure>
    <time_frame>PACU admission to discharge</time_frame>
    <description>Total opioid use in the post operative care unit (Mg of morphine equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in Post Anesthesia Care Unit</measure>
    <time_frame>Time in the post anesthesia care unit</time_frame>
    <description>Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain and time in the Post Anesthesia Care Unit.
The range is 0 pain to x time in minutes x 1 hour to 5 hour ( 60-300 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Use Discharge From Post Anesthesia Care Unit to 24 Hours After PACU Discharge.</measure>
    <time_frame>Discharge from PACU to 24 hours post operative after PACU discharge.</time_frame>
    <description>Opioid use in mg of morphine equivalents from discharge from the post anesthesia care unit to 24 hours after PACU discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Surgery</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Sevoflurane,Ultane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol,Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  Age 18-64

          -  Patients undergoing ambulatory surgery

          -  ASA PS I, II

        Exclusion Criteria:

          -  Chronic opioid use

          -  Pregnant patient

        Drop Out : patient or surgeon request
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>White PF, Kehlet H. Improving postoperative pain management: what are the unresolved issues? Anesthesiology. 2010 Jan;112(1):220-5. doi: 10.1097/ALN.0b013e3181c6316e. Review.</citation>
    <PMID>20010418</PMID>
  </reference>
  <reference>
    <citation>White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg. 2005 Nov;101(5 Suppl):S5-22. Review.</citation>
    <PMID>16334489</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Eger EI 2nd, Dutton RC, Sonner JM. Inhaled anesthetics have hyperalgesic effects at 0.1 minimum alveolar anesthetic concentration. Anesth Analg. 2000 Aug;91(2):462-6.</citation>
    <PMID>10910869</PMID>
  </reference>
  <reference>
    <citation>Hand R Jr, Riley GP, Nick ML, Shott S, Faut-Callahan M. The analgesic effects of subhypnotic doses of propofol in human volunteers with experimentally induced tourniquet pain. AANA J. 2001 Dec;69(6):466-70.</citation>
    <PMID>11837149</PMID>
  </reference>
  <reference>
    <citation>Cheng SS, Yeh J, Flood P. Anesthesia matters: patients anesthetized with propofol have less postoperative pain than those anesthetized with isoflurane. Anesth Analg. 2008 Jan;106(1):264-9, table of contents. doi: 10.1213/01.ane.0000287653.77372.d9.</citation>
    <PMID>18165589</PMID>
  </reference>
  <reference>
    <citation>Boccara G, Mann C, Pouzeratte Y, Bellavoir A, Rouvier A, Colson P. Improved postoperative analgesia with isoflurane than with propofol anaesthesia. Can J Anaesth. 1998 Sep;45(9):839-42.</citation>
    <PMID>9818105</PMID>
  </reference>
  <reference>
    <citation>Visser K, Hassink EA, Bonsel GJ, Moen J, Kalkman CJ. Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis. Anesthesiology. 2001 Sep;95(3):616-26.</citation>
    <PMID>11575532</PMID>
  </reference>
  <reference>
    <citation>Watson KR, Shah MV. Clinical comparison of 'single agent' anaesthesia with sevoflurane versus target controlled infusion of propofol. Br J Anaesth. 2000 Oct;85(4):541-6.</citation>
    <PMID>11064611</PMID>
  </reference>
  <reference>
    <citation>Röhm KD, Piper SN, Suttner S, Schuler S, Boldt J. Early recovery, cognitive function and costs of a desflurane inhalational vs. a total intravenous anaesthesia regimen in long-term surgery. Acta Anaesthesiol Scand. 2006 Jan;50(1):14-8. Retraction in: Acta Anaesthesiol Scand. 2011 Aug;55(7):903.</citation>
    <PMID>16451145</PMID>
  </reference>
  <reference>
    <citation>Montes FR, Trillos JE, Rincón IE, Giraldo JC, Rincón JD, Vanegas MV, Charris H. Comparison of total intravenous anesthesia and sevoflurane-fentanyl anesthesia for outpatient otorhinolaryngeal surgery. J Clin Anesth. 2002 Aug;14(5):324-8.</citation>
    <PMID>12208434</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5.</citation>
    <PMID>10740540</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Prinipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Outpatient</keyword>
  <keyword>Surgery</keyword>
  <keyword>Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited 12/2012-04/2014. 101 subjects were assessed for eligibility, 4 did not meet inclusion criteria and 7 declined to participate. 90 subjects were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevoflurane</title>
          <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in surgical case</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>case cancelled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unblinded</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sevoflurane</title>
          <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery Score 24 Hours Post Operative</title>
        <description>Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.</description>
        <time_frame>24 hours after the surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery Score 24 Hours Post Operative</title>
          <description>Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="163" upper_limit="181"/>
                    <measurement group_id="O2" value="176" lower_limit="163" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mg of Morphine Equivalents (IV)</title>
        <description>Total opioid use in the post operative care unit (Mg of morphine equivalents)</description>
        <time_frame>PACU admission to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
          </group>
        </group_list>
        <measure>
          <title>Mg of Morphine Equivalents (IV)</title>
          <description>Total opioid use in the post operative care unit (Mg of morphine equivalents)</description>
          <units>miligrams of morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="9.4" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain in Post Anesthesia Care Unit</title>
        <description>Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain and time in the Post Anesthesia Care Unit.
The range is 0 pain to x time in minutes x 1 hour to 5 hour ( 60-300 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
        <time_frame>Time in the post anesthesia care unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
          </group>
        </group_list>
        <measure>
          <title>Pain in Post Anesthesia Care Unit</title>
          <description>Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain and time in the Post Anesthesia Care Unit.
The range is 0 pain to x time in minutes x 1 hour to 5 hour ( 60-300 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
          <units>Pain Score * minutes in PACU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="195" upper_limit="330"/>
                    <measurement group_id="O2" value="240" lower_limit="165" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Use Discharge From Post Anesthesia Care Unit to 24 Hours After PACU Discharge.</title>
        <description>Opioid use in mg of morphine equivalents from discharge from the post anesthesia care unit to 24 hours after PACU discharge.</description>
        <time_frame>Discharge from PACU to 24 hours post operative after PACU discharge.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Use Discharge From Post Anesthesia Care Unit to 24 Hours After PACU Discharge.</title>
          <description>Opioid use in mg of morphine equivalents from discharge from the post anesthesia care unit to 24 hours after PACU discharge.</description>
          <units>mg morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="10" upper_limit="40"/>
                    <measurement group_id="O2" value="25" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.84</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time in the post anesthesia care unit.</time_frame>
      <desc>Nausea experienced in the post anesthesia care unit</desc>
      <group_list>
        <group group_id="E1">
          <title>Sevoflurane</title>
          <description>Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Nausea</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Development of nausea during the post operative period in the post operative care unit.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title vocab="Vomiting">Vomiting</sub_title>
                <description>Vomiting during the post operative period in the post anesthesia care unit.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We only studied patients undergoing outpatient laparoscopic gynecological surgery, therefore, our results cannot be generalizable to other surgical procedures.
We also administered remifentanil which is has been linked to hyperalgesia.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-4858</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

